Aqueous Humour and Intraocular Pressure: The Target of Every Glaucoma Drug
Not one glaucoma drug touches the optic nerve it is trying to save. Every single agent — the drop the patient instils at bedtime, the tablet swallowed in an emergency — works on one small circuit of fluid inside the front of the eye. The eye makes a clear liquid, circulates it, and drains it, and the pressure inside is simply the balance between how fast it is made and how freely it leaves. Understand that circuit and you understand the whole pharmacology: every drug either turns down the tap or opens the drain. Miss it, and the drug names are just a list to memorise.
A 68-year-old man comes to the optometrist for new reading glasses, seeing perfectly well as far as he can tell. Routine tonometry reads an intraocular pressure of 30 mmHg in each eye — roughly twice normal. He has no pain, no redness, no blurring; the disease has been utterly silent. But on examination the optic discs are cupped and hollowed, and a visual-field test reveals arc-shaped blind spots in his peripheral vision he had never noticed, because the brain quietly filled them in. This is chronic open-angle glaucoma: pressure has been slowly strangling the optic nerve for years. He will now start a single eye drop every night — a drug that never goes near the optic nerve, and instead nudges the plumbing of fluid at the front of his eye. To understand why that helps, you have to follow the fluid.
What glaucoma actually is
Glaucoma is a disease of the optic nerve, not merely a number on a pressure gauge. Glaucoma is a progressive optic neuropathy: the nerve fibres carrying vision from the retina to the brain are gradually lost, producing the characteristic cupped optic disc and a creeping loss of peripheral vision that ends, untreated, in blindness. The single most important and — crucially — the only treatable risk factor is raised intraocular pressure (IOP). That is why every drug in this section aims at pressure: we cannot yet regrow an optic nerve, but we can lower the pressure that is destroying it. Note the subtlety, though: a minority of patients suffer the same nerve damage at statistically "normal" pressures — normal-tension glaucoma — proving the disease is really about what the nerve can tolerate, not a magic number. Even here, lowering IOP still slows progression, which is why IOP remains the therapeutic target across the board.
The aqueous circuit: where the fluid comes from
The pressure inside the eye is set by a clear fluid called the aqueous humour — nothing to do with tears on the surface. It is made deep inside the eye by the ciliary body, a ring of tissue behind the iris. The ciliary epithelium actively secretes aqueous, and two of its machinery components are direct drug targets: the enzyme carbonic anhydrase, which drives the bicarbonate transport that pulls fluid out, and beta-adrenergic receptors, whose stimulation increases secretion. That single fact explains two whole drug classes before we have named one: block carbonic anhydrase, or block the beta receptor, and the ciliary body simply makes less fluid. The autonomic control here connects directly to the Autonomic Nervous System chapter — the ciliary body is studded with beta-adrenergic, alpha-adrenergic and muscarinic receptors, and glaucoma pharmacology is, at heart, applied autonomics.
Once made, the fluid takes a fixed one-way tour. Aqueous is secreted into the posterior chamber — the small space between the iris and the lens. From there it flows forward through the pupil into the anterior chamber, the larger space between the iris and the cornea, bathing and nourishing the avascular lens and cornea on the way (they have no blood supply and depend on this fluid). It then reaches the drainage angle — the corner where the iris meets the cornea — and leaves the eye. Production and this forward flow are continuous; the pressure is decided almost entirely at the exit.
The two drains — and why they matter to drugs
Aqueous leaves the eye by two routes, and knowing them is the key that unlocks the outflow drugs. The main exit is the conventional (trabecular) route: fluid filters through a sieve-like mesh called the trabecular meshwork, then into a ring-shaped vessel, Schlemm's canal, and away into the bloodstream. This route is pressure-dependent — the higher the pressure, the more it drains — and it is the site of most of the resistance that causes open-angle glaucoma. The second exit is the uveoscleral (unconventional) route: fluid seeps directly through the face of the ciliary body and out through the sclera, a slower, pressure-independent back door. This split is not academic trivia: prostaglandin analogues and alpha-2 agonists open the uveoscleral route, while pilocarpine and the newer rho-kinase inhibitors act on the trabecular meshwork. Every outflow drug is defined by which drain it opens.
Think of the eye as a sink with the tap running and the plug half-blocked. The water level — the pressure — depends only on two things: how fast the tap runs (aqueous production by the ciliary body) and how freely the drain lets water out (outflow through the meshwork and uveoscleral route). If the level rises dangerously, you have exactly two moves: turn down the tap, or clear the drain. Every glaucoma drug is one of those two moves. Beta-blockers, carbonic anhydrase inhibitors and alpha-2 agonists turn down the tap; prostaglandins, pilocarpine and rho-kinase inhibitors clear the drain. There is no third option — because there is no third variable.
The whole pharmacology in one equation
IOP = the balance of production against outflow. That balance is the entire drug map. Because pressure is set by production versus outflow, there are exactly two ways to lower it, and every class falls into one camp. To reduce production: topical beta-blockers such as timolol (the ciliary beta receptor), carbonic anhydrase inhibitors such as dorzolamide (topical) and acetazolamide (oral, for emergencies), and alpha-2 agonists such as brimonidine. To increase outflow: the prostaglandin analogues — latanoprost, bimatoprost, travoprost — which open the uveoscleral route and are the most powerful pressure-lowering drops available; the miotic pilocarpine, which contracts the ciliary muscle to pull open the trabecular meshwork; and the rho-kinase inhibitors, such as netarsudil, which relax the meshwork directly. Alpha-2 agonists are the useful dual-mechanism agents — they both cut production and modestly aid uveoscleral outflow. Each of these classes gets a full chapter: the mechanism, adverse effects and clinical niche of the prostaglandins, the beta-blockers and carbonic anhydrase inhibitors, and the alpha-agonists and miotics are covered in depth in their own sections.
- Glaucoma is a progressive optic neuropathy; raised IOP is the main — and the only treatable — risk factor.
- Aqueous humour is made by the ciliary body, flows posterior chamber → pupil → anterior chamber, and drains at the angle.
- Two drains: trabecular meshwork → Schlemm's canal (main, pressure-dependent) and the uveoscleral route (secondary).
- IOP is the balance of production versus outflow — the whole basis of glaucoma pharmacology.
- Reduce production: beta-blockers, carbonic anhydrase inhibitors, alpha-2 agonists.
- Increase outflow: prostaglandins & alpha-2 (uveoscleral); pilocarpine & rho-kinase inhibitors (trabecular).
Open-angle versus angle-closure: same fluid, opposite problem
The drainage angle can fail in two very different ways, and the distinction changes everything. In primary open-angle glaucoma — the common form — the angle looks anatomically open, but the trabecular meshwork has become quietly clogged, raising resistance and pressure over years. It is chronic, painless and silent, which is exactly why it steals peripheral vision unnoticed until late; the management is lifelong pressure-lowering drops to reach a target IOP. In angle-closure glaucoma the problem is mechanical: the peripheral iris physically bulges forward and covers the trabecular meshwork, slamming the drain shut. When this happens suddenly — acute angle-closure — pressure spikes to 50–70 mmHg within hours, and the eye becomes red, rock-hard and agonisingly painful, with a fixed mid-dilated pupil, blurred vision and haloes, often with nausea and vomiting. That is a sight-threatening emergency, covered in full in the Acute angle-closure chapter; the immediate treatment stacks production-reducers and outflow drugs together and adds pilocarpine to pull the iris off the drain, before definitive laser.
This is why the same pupil-dilating drop can be harmless in one patient and dangerous in another. Mydriatics — used routinely to examine the retina — bunch up the peripheral iris. In a normal wide angle that is irrelevant. But in an eye with an anatomically narrow angle, that bunched iris can suddenly block the trabecular meshwork and trigger acute angle-closure. The lesson threads through all of ophthalmology: before you dilate, think about the angle. The fluid physiology you just learned is not abstract — it predicts exactly which patients a routine drop can tip into an emergency.
How treatment is built — the stepwise principle
Chronic glaucoma is not treated to a pressure of zero but to a target IOP — a pressure low enough, for that individual nerve, to halt further loss. Treatment is stepwise. Because a prostaglandin analogue is the most effective single agent, is dosed just once daily, and has no systemic cardiorespiratory risk, it is almost always first-line. If one drug does not reach target, you add a second by a different mechanism — pairing a tap-closer with a drain-opener, for example timolol plus latanoprost — so their effects stack. Fixed-combination drops exist precisely to make this convenient. The overriding goal is never the number for its own sake but preventing progressive optic-nerve and visual-field loss: we lower pressure to protect vision the patient may not even realise is under threat. When drops are exhausted or intolerable, laser trabeculoplasty and surgery follow — but the pharmacology, resting entirely on the aqueous circuit in the figure above, is where every patient starts.
Newly diagnosed open-angle glaucoma, IOP 28 mmHg, target ~18 mmHg. Step 1: latanoprost 0.005% one drop at night (increases uveoscleral outflow) → IOP 21. Step 2: add timolol 0.5% each morning (reduces production) → IOP 17, target met, often given as a fixed combination. If still above target, a topical carbonic anhydrase inhibitor (dorzolamide) or an alpha-2 agonist (brimonidine) is added third. In an acute angle-closure emergency the logic inverts to speed: intravenous or oral acetazolamide plus topical timolol and brimonidine to shut production fast, topical pilocarpine to drag the iris off the meshwork, and urgent referral for laser peripheral iridotomy — every one of those drugs acting on the same circuit, just all at once.
- Open-angle glaucoma: angle open but meshwork clogged; chronic, silent; treat to a target IOP with lifelong drops.
- Angle-closure glaucoma: iris physically blocks the drain; acute form is a painful, red-eye emergency.
- Prostaglandin analogues are usually first-line: most effective, once daily, no systemic cardiorespiratory risk.
- Escalate by adding drugs of different mechanism so effects stack (e.g. prostaglandin + beta-blocker).
- The goal is preventing optic-nerve and visual-field loss, not achieving a number for its own sake.
- Thinking glaucoma equals high pressure. It is optic-nerve damage; normal-tension glaucoma proves a "normal" number does not exclude it, and pressure is only the modifiable risk factor.
- Forgetting that topical timolol is systemically absorbed. A beta-blocker eye drop can cause bronchospasm and bradycardia — avoid in asthma and heart block; teach punctal occlusion to cut absorption.
- Dilating a narrow-angle eye without a second thought. Mydriatics can precipitate acute angle-closure; check the angle before instilling a pupil-dilating drop.
A patient with chronic open-angle glaucoma needs a first drug to lower IOP. Which class is usually first-line because it is the most effective, once-daily, and free of systemic cardiorespiratory risk?
- Glaucoma is a progressive optic neuropathy; raised IOP is the main modifiable risk factor (but normal-tension glaucoma exists), so every drug targets pressure.
- Aqueous is made by the ciliary body, flows posterior chamber → pupil → anterior chamber, and drains by the trabecular (main) and uveoscleral routes.
- IOP = production versus outflow, giving two strategies: reduce production (beta-blockers, CAIs, alpha-2 agonists) or increase outflow (prostaglandins, pilocarpine, rho-kinase inhibitors, alpha-2).
- Open-angle is chronic and silent (treat to target IOP, prostaglandin first-line, add by mechanism); angle-closure physically blocks the drain and can be an emergency; the goal throughout is preventing optic-nerve and visual-field loss.
- Kanski's Clinical Ophthalmology: A Systematic Approach — Glaucoma; aqueous humour dynamics.
- American Academy of Ophthalmology, Basic and Clinical Science Course (BCSC), Section 10: Glaucoma.
- Bartlett & Jaanus, Clinical Ocular Pharmacology — Agents for glaucoma.
- Rang & Dale's Pharmacology — The eye and ocular pharmacology.
- National Institute for Health and Care Excellence (NICE) NG81: Glaucoma — diagnosis and management.
- European Glaucoma Society, Terminology and Guidelines for Glaucoma.
